Non-invasive tests for the prediction of primary hepatocellular carcinoma

Table 1 Studies reporting the role of aspartate aminotransferase to platelet ratio index in predicting hepatocellular carcinoma

Ref.	Etiology	Patients(n)	Follow-up (mo)	Region	HCC(n)	AUROC	Cut-off
Yu et al[31], 2006	HCV IFN-based treated	776	62.5	Asia	41	0.870	0.75 all patients 0.5 SVR, 1.5 no-SVR
Yu et al[31], 2006	HCV untreated	562	61.8	Asia	54	0.715	1.5
Reddy et al[33], 2015	HCV SVR IFN-treated	22	96	America	0	-	-
Reddy et al[33], 2015	HCV untreated	203	96	America	51	-	-
Hann et al[34], 2015	HBV	855	52.4	America; Asia	82	-	-
Chen et al[35], 2016	HCV SVR	540	41.4	Asia	15	-	> 0.5
Chen et al[35], 2016	HCV (no-SVR)	183	36.8	Asia	14	-	> 1.5
Kim et al[36], 2016	HBV	542	60	Asia	68	0.731	> 0.766
Lee et al[37], 2016	HCV	598	61.2	Asia	8		1
Ng et al[38], 2016	HCV	105	40.56	Asia	15	-	2
Wu et al[39], 2016	HCV SVR	1351	6 after SVR	Asia	49	-	0.7
Toyoda et al[21], 2017	HCV SVR; Training cohort	522	104	Asia	21	-	0.73
Toyoda et al[21], 2017	HCV SVR; Validation cohort	309	87,6	Asia	17	-	0,73
Cheung et al[22], 2017	PBC	144	82.8	Asia	12	0.77	0.54
Nishikawa et al[23], 2017	HBV	338	59.8	Asia	33	0.601	0.78
Ji et al[24], 2017	HCV SVR	34	41.4	Asia	5		1.5
Paik et al[16], 2018	HBV	1006	61.2	Asia	36	0.76	0.5
Chang et al[25], 2018	HCV (no-SVR)	800	53.5	Asia	100	-	2.57
Kim et al[26], 2018	ALD	924	36	Asia	83	0.61	1
Song et al[27], 2018	HBV	1014	46.8	Asia	37	-	0.5
Sou et al[28], 2018	HCV SVR; IFN-treatment	1351	6 after SVR	Asia	47	-	0,7
Sou et al[28], 2018	HCV no SVR	536	6 post treatment	Asia	75	-	0,7
Na et al[20], 2019	HCV SVR	295	89.2	Asia	12	0.89	2
Yoshimasu et al[29], 2019	HCV DAAs	211	6 after DAAs	Asia	2	-	-
Sahin et al[30], 2019	HBV; HBV+HDV	361	-	Europe	115	-	-
Kim et al[32], 2020	HBV	444	94.2	Asia	25	0.572	-

HCC: Hepatocellular carcinoma; AUROC: Area under receiving operating characteristics curve; HCV: Hepatitis virus C; IFN: Interferon; SVR: Sustained virologic response; HBV: Hepatitis virus B; PBC: Primary biliary cholangitis; ALD: Alcoholic liver disease; DAA: Direct acting antiviral agents; HDV: Hepatitis D virus.